ClinicalTrials.gg
Active, not recruitingNCT07505303Updated Jun 25, 2026

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

A Phase 2 interventional study of ECC4703 and Placebo in Adult Obesity and Weight Management, sponsored by Eccogene. Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Eccogene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

02

Conditions studied

  • Adult Obesity
  • Weight Management

Browse trials for

Keywords

  • Obesity
  • GLP-1
  • Weight Management
  • Semaglutide
  • MIST
  • ECC4703
  • THR-β
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 151 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of providing written and complying with all trial procedures.
  2. Willing to comply with requirements (as applicable to males and females of ).
  3. Obese with ≥30 kg/m\^2 and stable body weight within 6 months prior to screening.
  4. ≤6.5%.
  5. Estimated (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula).
  6. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF >8% at baseline (Week 9).

Exclusion criteria

Exclusion Criteria:

  1. History or current diagnosis of type 1 or type 2 diabetes mellitus.
  2. Weight change >5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication.
  3. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome.
  4. Use of GLP-1 agonist treatment within the last 6 months prior to screening.
  5. History or current evidence of a pituitary disorder.
  6. Have current treatment with or history (within 3 months prior to screening) of treatment with medications that may cause significant weight gain.
  7. or AST >1.5×, or ALP >1.5×ULN at screening.
  8. Documented evidence or clinical signs/symptoms of advanced liver disease including liver cirrhosis, portal hypertension, or hepatic decompensation.
  9. History of significant alcohol consumption for >3 consecutive months within a year prior to screening.
  10. Current or past therapy with THR-β agonists (eg, resmetirom).
  11. Active untreated hyperthyroidism or hyperthyroidism currently treated with antithyroid medications including methimazole or propylthiouracil.
  12. thyroid dysfunction including uncontrolled hypothyroidism or hyperthyroidism.
  13. History of bariatric surgery, fitting of a weight loss device, or intestinal bypass surgery within 5 years prior to screening.
  14. History of major surgery within 8 weeks prior to screening.
  15. Clinically relevant acute or chronic medical condition or unstable disease of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic system.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Arm 1: ECC4703 + semaglutide

    ECC4703 orally QD + semaglutide SC once weekly

    Drug: ECC4703 · Drug: Semaglutide

  • Placebo comparator
    Arm 2: Placebo + semaglutide

    Placebo orally QD + semaglutide SC once weekly

    Drug: Placebo · Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change in Body Weight from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  2. Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  3. Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis

    Time frame: Baseline (Week 9) to Week 20

  4. Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis

    Time frame: Baseline (Week 9) to Week 20

  5. Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF

    Time frame: Baseline (Week 9) to Week 20

Secondary outcomes

  1. Change in Percentage Lean Mass as Measured by DXA

    Time frame: Baseline (Week 9) to Week 20

  2. Change in Percentage Total Body Fat Mass as Measured by DXA

    Time frame: Baseline (Week 9) to Week 20

  3. Change in Percentage Visceral Fat Mass as Measured by DXA

    Time frame: Baseline (Week 9) to Week 20

  4. Change in Glycemic Parameters from Baseline (Week 9) to Week 20

    Change in HbA1c and fasting plasma glucose levels from baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  5. Change in Lipid Parameters from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  6. Change in Body Weight (kg) from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  7. Proportion of Participants Achieving ≥2% and ≥3% Reduction in Body Weight from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  8. Change in Alanine Aminotransferase (ALT) Levels from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  9. Change in Aspartate Aminotransferase (AST) Levels from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  10. Change in Alkaline Phosphatase (ALP) Levels from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  11. Change in Gamma-Glutamyl Transferase (GGT) Levels from Baseline (Week 9) to Week 20

    Time frame: Baseline (Week 9) to Week 20

  12. Frequency of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose through Week 20 (or end of study visit)

  13. Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose through Week 20 (or end of study visit)

  14. Laboratory Safety Evaluations

    changes in clinical laboratory parameters, including hematology, serum chemistry, and urinalysis.

    Time frame: Baseline through Week 20

  15. Changes in 12-Lead Electrocardiogram (ECG) Parameters

    Change in QT Interval, etc

    Time frame: Baseline through Week 20

  16. Changes in Vital Signs Findings

    including blood pressure, etc

    Time frame: Baseline through Week 20

  17. Changes in Physical Examination Findings

    including blood pressure, etc

    Time frame: Baseline through Week 20

07

Study locations

15 sites
  • Central Research Associates - Flourish - PPDS
    Birmingham, Alabama 35205, United States
  • Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS
    Anaheim, California 92081, United States
  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS
    Los Alamitos, California 90720, United States
  • AES - DRS - Optimal Research Florida - Melbourne
    Melbourne, Florida 32934, United States
  • ForCare Clinical Research - CenExel FCR - PPDS
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research - CenExel ACMR - PPDS
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta - CenExel - PPDS
    Decatur, Georgia 30030, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis
    Richfield, Minnesota 55423, United States
  • Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research - Durham - PPDS
    Durham, North Carolina 27701, United States
  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS
    Cincinnati, Ohio 45246, United States
  • Velocity Clinical Research - Providence - PPDS
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research - Dallas - PPDS
    Dallas, Texas 75230, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
    San Antonio, Texas 78229, United States
  • Flourish Research - San Antonio - PPDS
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 6 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Apr 1, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Oct 15, 2026
CompletionEst.
Oct 15, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505303
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Mar 23, 2026
Primary completion
Oct 15, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ECC4703

Start the discussion